ORNBV Orion Oyj Class B

Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation

Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation

ORION CORPORATION  STOCK EXCHANGE RELEASE 12 JANUARY 2021 at 10.15 EET

        

Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation

The Nomination Committee of Orion Corporation has on 12 January 2021 given to the company’s Board of Directors its recommendation for the proposal to the Annual General Meeting of 2021 concerning the composition of the Board of Directors to be elected by the meeting. The Committee recommends that the following proposal be presented to the AGM of 2021:

The number of Board members would be eight.

The present members of the Board, Kari Jussi Aho, Pia Kalsta, Ari Lehtoranta, Timo Maasilta, Hilpi Rautelin, Eija Ronkainen and Mikael Silvennoinen would be elected for the next term of office and Veli-Matti Mattila,  M.Sc (Tech.), MBA would be elected as a new member.



Mikael Silvennoinen would be re-elected as the Chairman of the Board.

Personal information of Veli-Matti Mattila:

Born: 1961

Education and profession: M.Sc (Tech.), MBA, CEO

Key work experience:

  • Elisa Corporation, CEO, 2003-
  • Oy LM Ericsson Ab, Finland, CEO, 1997-2003
  • Ericsson, Nordic and Baltic, Deputy Head, 2001-2003
  • Ericsson, US, Product Marketing Manager, 1994-1997
  • Ericsson, Software Designer, Product Manager, Sales Director, 1986-1989, 1990-1993
  • Ascom Hasler AG, Switzerland, Specialist, 1989-1990

Current key positions of trust:

Member of the Board: Service Sector Employers Palta 2019-, Finnish Business and Policy Forum EVA 2017-, The Research Institute of the Finnish Economy Etla 2017-, The Mannerheim Foundation 2017-

Other: Member of the Executive Committee of the Board of Service Sector Employers Palta 2019-, Member of The National Emergency Supply Council 2008-, Member of the Supervisory Board of The Finnish Fair Association 2007-

Previous key positions of trust:

Chairman of the Board: Confederation of Finnish Industries EK 2017-2018, Service Sector Employers Palta 2015-2016

Vice Chairman of the Board: Service Sector Employers Palta 2014

Member of the Board: Sampo Plc 2009-2020, Confederation of Finnish Industries EK 2015-2016 and 2005-2006, Service Sector Employers Palta 2013, Confederation of Finnish Industry and Employers TT 2004

Other: Chairman of the Executive Committee of the Board of Service Sector Employers Palta 2015-2016, Vice Chairman 2014

The Nomination Committee also announces as its recommendation that the following remunerations would be paid to the Board of Directors:

As an annual fee, the Chairman would receive EUR 90,000, the Vice Chairman would receive EUR 55,000 and the other members would receive EUR 45,000 each. However, if a member of the board acts as the Chairman of the Audit Committee or the R&D Committee, her/his annual fee would be EUR 55,000. In addition, as a fee for each meeting attended, the Chairman would receive EUR 1,200, the Vice Chairman would receive EUR 900 and the other members would receive EUR 600 each. The travel expenses of the Board members would be paid in accordance with the previously adopted practice. The aforementioned meeting attendance fees would also be paid to the Chairmen and to the members of the committees established by the Board.

Of the above-mentioned annual fees, 60% would be paid in cash and 40% in Orion Corporation B-shares, which would be acquired for the members over the period 28 April–4 May 2021 from the stock exchange in amounts corresponding to EUR 36,000 for the Chairman, EUR 22,000 for the Vice Chairman and for the board members acting as the Chairmen of the Audit Committee and the R&D Committee and EUR 18,000 for each of the other members. The part of the annual fee that is to be paid in cash corresponds to the approximate sum necessary for the payment of the income taxes on the fees and would be paid no later than 31 May 2021. The annual fees shall encompass the full term of office of the Board of Directors. In addition, the company would pay the transfer tax related to the part of the annual fee of the Board of Directors paid in shares.

The Nomination Committee has not given its recommendation for the remunerations to the Board of Directors, but the matter will be proposed by a shareholder at the AGM.

The Nomination Committee notes that the annual fee of the Chairman of the Board decided in 2020 was EUR 84,000 and the annual fee of a member of the Board EUR 42,000, so they would now be increased. A change from the previous one would also be that the annual fee of a member of the Board of Directors who chairs the Audit Committee or the R&D Committee would be the same as that of the Vice Chairman of the Board. In other respects, the fees would remain unchanged. The annual fees of the Board of Directors were last time changed in 2017.

The members of the Nomination Committee belonging to the Board of Directors did not participate in the consideration or decision-making of the recommendation on the remuneration of the Board of Directors.

The Nomination Committee has consisted of the following members: Heikki Westerlund, Chairman, Annika Ekman, Petteri Karttunen, Timo Maasilta, Mikael Silvennoinen and Jukka Ylppö. 

Orion Corporation

Timo Lappalainen

President and CEO
   Olli Huotari

SVP, Corporate Functions
   
             

  

                                                                                                            

Contact person:

Heikki Westerlund, Chairman of the Nomination Committee

Tel. +358 (0)50 559 6580







Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland





Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled pulmonary medication under Easyhaler® device portfolio. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

 



EN
12/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion Group Interim Report January–September 2025

Orion Group Interim Report January–September 2025 ORION CORPORATION INTERIM REPORT 1–9/2025 28 OCTOBER 2025 at 12:00 EET Orion Group Interim Report January–September 2025 July–September 2025 Highlights Net sales totalled EUR 423.2 (July–September 2024: 471.3) million Operating profit was EUR 121.0 (202.0) millionNet sales and operating profit of the comparison period include EUR 130 million of major milestone paymentsBasic earnings per share were EUR 0.68 (1.14)Cash flow from operating activities per share was EUR 0.55 (0.48)The outlook for 2025 has been specified: Net sales are estimat...

 PRESS RELEASE

Orion-konsernin osavuosikatsaus tammi–syyskuu 2025

Orion-konsernin osavuosikatsaus tammi–syyskuu 2025 ORION OYJ OSAVUOSIKATSAUS 1–9/2025 28.10.2025 klo 12:00 Orion-konsernin osavuosikatsaus tammi–syyskuu 2025 Heinä–syyskuu 2025 lyhyesti Liikevaihto oli 423,2 miljoonaa euroa (471,3 miljoonaa euroa 7–9/2024)Liikevoitto oli 121,0 (202,0) miljoonaa euroaVertailukauden liikevaihto ja -voitto sisältävät 130 miljoonaa euroa merkittäviä etappimaksujaLaimentamaton osakekohtainen tulos oli 0,68 (1,14) euroaOsakekohtainen liiketoiminnan rahavirta oli 0,55 (0,48) euroaVuoden 2025 näkymäarviota on täsmennetty: Liikevaihdon arvioidaan olevan 1 640–1 ...

 PRESS RELEASE

49,164 Orion Corporation A shares converted into B shares

49,164 Orion Corporation A shares converted into B shares ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 24 OCTOBER 2025 at 9.00 EEST         49,164 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 49,164 A shares have been converted into 49,164 B shares. The conversion has been entered into the Trade Register on 24 October 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 31,841,81...

 PRESS RELEASE

49 164 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi

49 164 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi ORION OYJ        PÖRSSITIEDOTE – MUUT PÖRSSIN SÄÄNTÖJEN NOJALLA JULKISTETTAVAT TIEDOT         24.10.2025 KLO 9.00          49 164 kpl Orion Oyj:n A-osaketta muunnettu B-osakkeiksi Orion Oyj:n yhtiöjärjestyksen 3 §:n nojalla on muunnettu 49 164 A-osaketta 49 164 B-osakkeeksi. Muuntaminen on merkitty kaupparekisteriin 24.10.2025. Orion Oyj:n osakkeiden kokonaismäärä on 141 134 278 kpl. Muuntamisen jälkeen A-osakkeita on 31 841 817 kpl ja B-osakkeita 109 292 461 kpl. Yhtiön osakkeiden tuottama äänimäärä muunnon jälkeen on yhteensä 7...

 PRESS RELEASE

Orion and Abzena announce exclusive commercial license for Abzena’s an...

Orion and Abzena announce exclusive commercial license for Abzena’s antibody ORION CORPORATION PRESS RELEASE 23 OCTOBER 2025 at 15:30 EEST         Orion and Abzena announce exclusive commercial license for Abzena’s antibody Orion Corporation (“Orion”) and Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, today announced that Orion has obtained an exclusive, focused commercial license to one of Abzena’s monoclonal antibodies (mAbs) that targets a cancer of high clinical unmet need. The antibody will strengthen Orion’s broad oncology-focused drug Resear...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch